

Therapy Trends: Rheumatoid Arthritis -- Consensus Outlook Module

<https://marketpublishers.com/r/TA59EDC74D8EN.html>

Date: July 2012

Pages: 245

Price: US\$ 4,995.00 (Single User License)

ID: TA59EDC74D8EN

Abstracts

Analyse the latest global RA market players and products, and start mapping your future market parameters with Therapy Trends' Consensus Outlook: Rheumatoid Arthritis, which includes the following comprehensive resources:

An in-depth 5-year forecast report based on analyst consensus

Detailed data spreadsheets comparing critical market parameters

Regular updates over the next 12 months, after major market events

Consensus Outlook Module Features

Historical RA sales from 2006–2011

Forecast RA sales from 2012-2016

Key competitors and drug developers

Predicted product positioning

Current and late-stage pipeline drugs

Future event mapping to forecast data points

Comparative clinical trial results

Meticulous Methodology

Consensus Outlook: Rheumatoid Arthritis is a data analysis module compiled from meticulous FirstWord research. Its historical sales data (2006–11) is based on company information. The five-year (2012-16) product level sales forecasts are consensus projections derived from a comprehensive selection of continually assessed equity research reports.

This Consensus Outlook collates and evaluates the latest relevant reports and forecasts published by leading equity research analysts. This information is fed into the Therapy Trends Forecast model to give unbiased consensus forecasts.

Overall, this module offers you independent, unbiased, accurate forecasts from leading financial institutions with the most intimate commercial knowledge of the competitive players and products in this disease sector.

Forecast Spreadsheets

Save valuable time by focusing on FirstWord's 5-year RA forecast data with our detailed Excel spreadsheets. Consensus Outlook: Rheumatoid Arthritis allows you to quickly compare various market parameters by:

Market size

International and US markets

Product sales

Brand, company and drug class

Company forecasts

Mechanism of action

Consensus Updates

Stay one step ahead of your competition with FirstWord's Consensus Outlook updates. Receive these directly over the next 12 months, following major RA market events, within days of each event's occurrence.

Consensus Outlook Benefits:

Chart predicted market growth and product sales

Map your own market parameters

Tailor your strategic and investment focus

Assess your current and future sales resources

Set proactive launches and branding strategies

Contents

CONSENSUS OUTLOOK

INTERACTIVE DATA ANALYSIS FILE (EXCEL)

TABS:

Market size
Product sales
Company forecast
Mechanism of action
Events

MARKET ANALYSIS FILE (PDF)

CONTENTS:

FirstWord Analysis Highlights
Rheumatoid Arthritis marketplace
Key Rheumatoid Arthritis developers
Rheumatoid arthritis class dynamics
Enbrel (etanercept; Amgen/Pfizer/Takeda) forecast
Humira (adalimumab; Abbott/Eisai) forecast
Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) forecast
Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) forecast
Cimzia (certolizumab; UCB) forecast
Orencia (abatacept; Bristol-Myers Squibb) forecast
Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai) forecast
Actemra/RoActemra (tocilizumab; Chugai/Roche) forecast
Tofacitinib (CP-690,550; Pfizer/Takeda) forecast
Fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals) forecast
Secukinumab (AIN457; Novartis) forecast

Figures

FIGURES:

Rheumatoid Arthritis worldwide market sales value, 2006–2016

Growth and market share of the US and international RA markets, 2006–16

Rheumatoid Arthritis worldwide market sales value, 2006–2016

Rheumatoid Arthritis worldwide market share difference from 2006 to 2016

Rheumatoid Arthritis worldwide market sales value split by class, 2011

Sales dynamics of leading Alzheimer's disease brands, 2011-2016

Sales dynamics of Enbrel (etanercept; Amgen/Pfizer/Takeda), 2006-2016

Enbrel (etanercept; Amgen/Pfizer/Takeda) sales by region worldwide (\$m), 2006–2016

Sales dynamics of Humira (adalimumab; Abbott/Eisai), 2006-2016

Humira (adalimumab; Abbott/Eisai) sales by region worldwide (\$m), 2006–2016

Sales dynamics of Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe), 2006-2016

Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) sales by region worldwide (\$m), 2006–2016

Sales dynamics of Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe), 2009-2016

Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) sales by region worldwide (\$m), 2009–2016

Sales dynamics of Cimzia (certolizumab; UCB), 2009-2016

Cimzia (certolizumab; UCB) sales by region worldwide (\$m), 2009–2016

Sales dynamics of Orencia (abatacept; Bristol-Myers Squibb), 2006-2016

Orencia (abatacept; Bristol-Myers Squibb) sales by region worldwide (\$m), 2009–2016

Sales dynamics of Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai), 2006-2016

Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai) sales by region worldwide (\$m), 2009–2016

Sales dynamics of Actemra/RoActemra (tocilizumab; Chugai/Roche), 2006-2016

Actemra/RoActemra (tocilizumab; Chugai/Roche) sales by region worldwide (\$m), 2009–2016

Sales dynamics of tofacitinib (CP-690,550; Pfizer/Takeda), 2012-2016

Tofacitinib (CP-690,550; Pfizer/Takeda) sales by region worldwide (\$m), 2012–2016

Sales dynamics of fostamatinib disodium (R788), 2011-2016

Sales dynamics of fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals), 2014-2016

Sales dynamics of secukinumab (AIN457; Novartis), 2014-2016

Secukinumab (AIN457; Novartis) sales by region worldwide (\$m), 2014–2016

Tables

TABLES:

Sales and growth of regions for Rheumatoid Arthritis, 2011–2016

Leading companies in the branded worldwide Rheumatoid Arthritis market, 2011–2016

Sales and growth of classes in Rheumatoid Arthritis, 2011–2016

Expected key impacting factors on the global revenues of Enbrel (etanercept; Amgen/Pfizer/Takeda) in Rheumatoid Arthritis, 2011–2016

Expected key impacting factors on the global revenues of Humira (adalimumab; Abbott/Eisai) in Rheumatoid Arthritis, 2011–2016

Expected key impacting factors on the global revenues of Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) in Rheumatoid Arthritis, 2011–2016

Expected key impacting factors on the global revenues of Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) in Rheumatoid Arthritis, 2011–2016

Expected key impacting factors on the revenues of Cimzia (certolizumab; UCB) in Rheumatoid Arthritis, 2011–2016

Expected key impacting factors on the revenues of Orencia (abatacept; Bristol-Myers Squibb) in Rheumatoid Arthritis, 2011–2016

Expected key impacting factors on the revenues of Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai) in Rheumatoid Arthritis, 2011–2016

Expected key impacting factors on the revenues of Actemra (tocilizumab) in Rheumatoid Arthritis, 2011–2016

Expected key impacting factors on the revenues of tofacitinib (CP-690,550; Pfizer/Takeda) in Rheumatoid Arthritis, 2011–2016

Expected key impacting factors on the revenues of fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals) in Rheumatoid Arthritis, 2011–2016

Expected key impacting factors on the revenues of secukinumab (AIN457; Novartis) in Rheumatoid Arthritis, 2014–2016

I would like to order

Product name: Therapy Trends: Rheumatoid Arthritis -- Consensus Outlook Module

Product link: <https://marketpublishers.com/r/TA59EDC74D8EN.html>

Price: US\$ 4,995.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TA59EDC74D8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970